SI-BONE, Inc.SIBN
What SI-BONE, Inc. does.
We are a leader in developing innovative procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific innovation. As pioneers of minimally invasive treatment for sacroiliac joint dysfunction and degeneration, we have developed a deep competency in addressing the challenges of low-density bone in the sacrum. With our additive manufacturing, or 3D-printing, experience developed in sacroiliac fusion, we have established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma.
We market our products primarily with a direct sales force as well as a number of third-party sales agents in the United States, and with a combination of a direct sales force, sales agents and resellers in other countries. As of December 31, 2025, over 140,000 procedures have been performed using our products since we introduced iFuse in 2009.
Our products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Since launching our first generation iFuse in 2009, we have launched multiple implant product lines, including iFuse 3D in 2017, iFuse TORQ in 2021, iFuse Bedrock Granite in 2022, and iFuse INTRA and iFuse TORQ TNT in 2024. In the United States, iFuse, iFuse 3D, iFuse TORQ and iFuse Bedrock Granite have clearances for applications in sacroiliac joint dysfunction, adult spinal deformity and pelvic trauma. iFuse TORQ TNT has clearances for applications in pelvic trauma and sacroiliac joint dysfunction. In the European Economic Areas, iFuse, iFuse 3D and iFuse TORQ have been CE marked for applications in sacroiliac joint dysfunction, adult spinal deformity and pelvic fracture fixation.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $73.4M | $90.2M | $106.4M | $138.9M | $167.2M | $200.9M |
| Net income | -$43.7M | -$56.6M | -$61.3M | -$43.3M | -$30.9M | -$18.9M |
| Free cash flow | -$33.2M | -$45.9M | -$51.2M | -$26.5M | -$22.9M | -$9.1M |
More on SIBN.
- SI-BONE, Inc. summary
- SI-BONE, Inc. financial statements
- SI-BONE, Inc. key metrics
- SI-BONE, Inc. health scores and style box
- SI-BONE, Inc. earnings
- SI-BONE, Inc. dividends
- SI-BONE, Inc. valuation
- SI-BONE, Inc. ownership and insiders
- SI-BONE, Inc. peers
Figures from SI-BONE, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.